Skip to Content

Rifapentine Pregnancy and Breastfeeding Warnings

Rifapentine is also known as: Priftin

Rifapentine Pregnancy Warnings

In one clinical study, six patients randomized to rifapentine became pregnant during treatment. There were 2 normal deliveries, 2 first trimester spontaneous abortions, one elective abortion, and one lost to follow-up. Of the two patients with spontaneous abortions, one had a history of ethanol abuse and the other had HIV infection. When administered during the last few weeks of pregnancy, rifampin, a chemically related agent, has rarely been associated with maternal and neonatal hemorrhagic complications stemming from vitamin K deficiency. Prophylactic vitamin K is sometimes given, particularly if dietary vitamin K intake is inadequate. If rifapentine is used during the latter weeks of pregnancy, appropriate clotting parameters should be assessed in both patient and neonate.

Rifapentine has been assigned to pregnancy category C. Animal studies using doses similar to or less than the human dose (based on body surface area) have revealed evidence of teratogenicity. There are no controlled studies in human pregnancy. Rifapentine should only be given during pregnancy when benefit outweighs risk.

See references

Rifapentine Breastfeeding Warnings

There are no data on the excretion of rifapentine into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. Eggermont E, Logghe N, Van De CAsseye M, et al. "Haemorrhagic disease of the newborn in the offspring of rifampicin and isoniazid treated mothers." Acta Paediatr Belg 29 (1976): 87-90
  2. "Product Information. Priftin (rifapentine)." Hoechst Marion-Roussel Inc, Kansas City, MO.

References for breastfeeding information

  1. "Product Information. Priftin (rifapentine)." Hoechst Marion-Roussel Inc, Kansas City, MO.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.